Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
Provided By GlobeNewswire
Last update: May 14, 2025
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial
Read more at globenewswire.com
